secwatch.observer — SEC 8-K summary
======================================

Issuer:     VivoSim Labs, INC. (VIVS)
CIK:        0001497253
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0000950170-25-026097
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organovo sells FXR program to Eli Lilly for $10M upfront; faces Nasdaq delisting
--------------------------------------------------------------------------------

- Lilly to buy Organovo's FXR program for $10M upfront ($9M at close, $1M escrow) + up to $50M in milestones.
- Lead asset FXR314, an oral FXR agonist for IBD, to be advanced to Phase 2 by Lilly.
- Organovo faces Nasdaq delisting: stockholders' equity of $364K as of Dec 31, 2024, below $2.5M minimum.
- Hearing before Nasdaq panel scheduled Feb 27, 2025; company may pursue reverse stock split to regain bid price compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1497253/000095017025026097/0000950170-25-026097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1497253/000095017025026097/onvo-20250219.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-026097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer